Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$110.94 USD
+1.05 (0.96%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$110.94 USD
+1.05 (0.96%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Abbott (ABT) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Abbott (ABT) stood at $103.23, denoting a -0.19% change from the preceding trading day.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
DexCom (DXCM) Declines on Potential Competition for Stelo (revised)
by Zacks Equity Research
DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.
DexCom (DXCM) Declines on Potential Competition for Stelo
by Zacks Equity Research
DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Abbott (ABT) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
The latest trading day saw Abbott (ABT) settling at $101.74, representing a +1% change from its previous close.
Implied Volatility Surging for Abbot Laboratories (ABT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Abbot Laboratories (ABT) stock based on the movements in the options market lately.
Abbott (ABT) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Abbott (ABT) concluded the recent trading session at $103.95, signifying a -0.27% move from its prior day's close.
Wall Street Analysts See Abbott (ABT) as a Buy: Should You Invest?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Abbott (ABT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Here's Why You Should Hold on to Abbott (ABT) Stock for Now
by Zacks Equity Research
Abbott's (ABT) share recovery in the Nutrition business buoys optimism.
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: UnitedHealth, Danaher, Abbott and Ark Restaurants
by Zacks Equity Research
UnitedHealth, Danaher, Abbott and Ark Restaurants are included in this Analyst Blog.
Top Stock Reports for UnitedHealth, Danaher & Abbott
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Danaher Corporation (DHR) and Abbott Laboratories (ABT), as well as a micro-cap stock Ark Restaurants Corp. (ARKR).
Abbott (ABT) Down 0.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
The Zacks Analyst Blog Highlights Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips
by Zacks Equity Research
Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips are included in this Analyst Blog.
Q1 Earnings Season Scorecard and Fresh Analyst Reports for Tesla, JNJ & Netflix
by Sheraz Mian
Today's Research Daily features the Q1 earnings season scorecard and updated analyst reports on Tesla (TSLA), JNJ (JNJ), Netflix (NFLX) and others.
Is Trending Stock Abbott Laboratories (ABT) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
PBH vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBH vs. ABT: Which Stock Is the Better Value Option?
Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NOBL
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
by Zacks Equity Research
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Q1 Earnings Review
by Zacks Equity Research
Q1 Earnings Review
Markets Try to Shake Off April Blues
by Mark Vickery
Late March highs -- including all-time S&P levels -- have given way to profit-taking and existential concerns.
Abbott (ABT) Q1 Earnings Beat Estimates, Margins Contract
by Zacks Equity Research
Abbott (ABT) delivers double-digit organic sales growth in its underlying base business in the first quarter of 2024.
Abbott (ABT) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Abbott (ABT) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 2.08% and 1.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?